Pfizer (PFE) has received a new Hold rating, initiated by Citi analyst, Geoff Meacham.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Geoff Meacham’s rating is based on a combination of factors that present a balanced outlook for Pfizer. While the company has demonstrated strong operational performance, particularly with non-COVID product revenues and its oncology franchise, there are significant challenges on the horizon. The upcoming Loss of Exclusivity period and pressures from Medicare Part D are notable concerns that temper a more optimistic view.
Despite these challenges, Pfizer’s strategic moves, such as its cost-saving initiatives and a favorable agreement with the Trump administration, have created a more stable environment. Additionally, the acquisition of Metsera signals a promising entry into the anti-obesity market, which could provide long-term growth opportunities. However, the potential risks associated with pipeline disappointments and competitive pressures contribute to the Hold rating, reflecting a cautious stance until more clarity emerges.
According to TipRanks, Meacham is a 5-star analyst with an average return of 7.2% and a 56.69% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol-Myers Squibb, and Regeneron.
In another report released on November 26, Berenberg Bank also maintained a Hold rating on the stock with a $25.00 price target.